Merus and Biohaven Partner to Develop Novel Bispecific ADCs

Merus N.V. and Biohaven Ltd. have announced a strategic collaboration and licensing agreement to co-develop three bispecific antibody-drug conjugates (ADCs). This partnership will harness Merus' Biclonics® technology platform for engineering bispecific antibodies, alongside Biohaven’s advanced ADC conjugation and payload technologies. Under the agreement, Biohaven will lead the preclinical generation of ADCs, with both companies sharing development costs and commercialization responsibilities upon mutual consent.

Leaders from both companies highlighted the collaboration's potential to transform oncology treatments. Bill Liang, CEO of Biohaven, emphasized the opportunity to combine technologies for innovative solutions, while Dr. Hui Liu, CSO of Merus, underscored the effort to address unmet needs in cancer care. By integrating expertise in bispecific antibody engineering and ADC innovation, this partnership aims to accelerate the development of next-generation therapies for cancer patients worldwide.